S&P Futures
3,258.50-16.50(-0.50%)Dow Futures
26,926.00-129.00(-0.48%)Nasdaq Futures
10,916.25-72.75(-0.66%)
Mirati Therapeutics, Inc. (MRTX)
- Barrons.com
High Hopes for Amgen and Gilead at Europe’s Biggest Cancer Research Conference
Europe’s biggest conference for cancer researchers will be a virtual affair this weekend, but it is still expected to be a big deal for companies like Amgen and for Immunomedics, which just agreed to a $21 billion acquisition by Gilead Sciences.
- Moody's
Qorvo, Inc. -- Moody's announces completion of a periodic review of ratings of Qorvo, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Qorvo, Inc. New York, September 18, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Qorvo, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- PR Newswire
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or metastatic urothelial carcinoma. Sitravatinib is an investigational multi-targeted tyrosine kinase inhibitor that distinguishes itself by potently targeting the TAM (TYRO3, Axl, Mer) and split (VEGFR2, KIT) family receptors. The combination of sitravatinib with nivolumab demonstrated promising clinical activity in checkpoint inhibitor-naïve, platinum-refractory patients. These data were presented today in a mini oral session at the European Society for Medical Oncology Virtual Congress (ESMO) 2020 by Dr. Pavlos Msaouel, M.D., Ph.D.
